(Q30992721)

English

Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III ran

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III ran (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

1 reference

based on heuristic

inferred from title

object named as

Kevin J Horgan

8

0 references

author name string

Richard J Gralla

1

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

Ronald de Wit

2

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

Jorn Herrstedt

3

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

Alexandra D Carides

4

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

Juliana Ianus

5

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

Julie Guoguang-Ma

6

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

Judith K Evans

7

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

language of work or name

0 references

publication date

1 August 2005

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

104

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

864-868

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Ondansetr

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21222

21 January 2018

Changes in serotonin metabolism in cancer patients: its relationship to nausea and vomiting induced by chemotherapeutic drugs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21222

21 January 2018

Treatment of chemotherapy-induced emesis in the 1990s: impact of the 5-HT3 receptor antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21222

7 January 2021

based on heuristic

inferred from DOI database lookup

Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21222

7 January 2021

based on heuristic

inferred from DOI database lookup

Drug treatment of chemotherapy-induced delayed emesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21222

7 January 2021

based on heuristic

inferred from DOI database lookup

Why Do We Need Another Antiemetic? Just Ask

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21222

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of a susceptibility to motion sickness on the side effects of cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21222

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy-related nausea and vomiting: etiology and management

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21222

7 January 2021

based on heuristic

inferred from DOI database lookup

Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21222

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors influencing cisplatin-induced emesis. Definition and validation of a predictive logistic model

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21222

7 January 2021

based on heuristic

inferred from DOI database lookup

Pretreatment factors predicting the development of postchemotherapy nausea and vomiting in Chinese breast cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21222

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduced maintenance of complete protection from emesis for women during chemotherapy cycles

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21222

7 January 2021

based on heuristic

inferred from DOI database lookup

Proposal for classifying the acute emetogenicity of cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21222

7 January 2021

based on heuristic

inferred from DOI database lookup

Serotonin mechanisms in chemotherapy-induced emesis in cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21222

7 January 2021

based on heuristic

inferred from DOI database lookup

Pathophysiology, severity, pattern, and risk factors for carboplatin-induced emesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21222

7 January 2021

based on heuristic

inferred from DOI database lookup

Neuropharmacology of emesis and its relevance to anti-emetic therapy. Consensus and controversies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21222

7 January 2021

based on heuristic

inferred from DOI database lookup

Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21222

7 January 2021

based on heuristic

inferred from DOI database lookup

The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 St

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21222

7 January 2021

based on heuristic

inferred from DOI database lookup

Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21222

7 January 2021

based on heuristic

inferred from DOI database lookup

The severity and pattern of emesis following different cytotoxic agents

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21222

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.21222

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30992721&oldid=1584460565"